[A26-102] Belantamab mafodotin (multiple myeloma; combination with bortezomib and dexamethasone) – Addendum to Project A26-38
Last updated 01.10.2026
Project no.:
A26-102
Commission:
Commission awarded on 11.08.2026 by the Federal Joint Committee (GBA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with relapsed or refractory multiple myeloma
Result of dossier assessment:
- Patients who have received one to three prior therapies: unchanged after addendum: added benefit not proven
- Patients who have received at least four prior therapies: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-102
| Project no. | Title | Status |
|---|---|---|
| A26-38 | Belantamab mafodotin (multiple myeloma; combination with bortezomib and dexamethasone) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (GBA)
01-10-2026 A G-BA decision was published.
GBA documents on this decision